Literature DB >> 18337382

Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.

Gunnstein Norheim1, Abraham Aseffa, Mohammed Ahmed Yassin, Getahun Mengistu, Afework Kassu, Dereje Fikremariam, Wegene Tamire, Yared Merid, E Arne Høiby, Dominique A Caugant, Elisabeth Fritzsønn, Torill Tangen, Berhanu Melak, Degu Berhanu, Morten Harboe, Jan Kolberg, Einar Rosenqvist.   

Abstract

Dissecting the specificities of human antibody responses following disease caused by serogroup A meningococci may be important for the development of improved vaccines. We performed a study of Ethiopian patients during outbreaks in 2002 and 2003. Sera were obtained from 71 patients with meningitis caused by bacteria of sequence type 7, as confirmed by PCR or culture, and from 113 Ethiopian controls. Antibody specificities were analyzed by immunoblotting (IB) against outer membrane antigen extracts of a reference strain and of the patients' own isolates and by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) levels against lipooligosaccharide (LOS) L11 and the proteins NadA and NspA. IB revealed that the main antigens targeted were the proteins PorA, PorB, RmpM, and Opa/OpcA, as well as LOS. MenA disease induced significant increases in IgG against LOS L11 and NadA. The IgG levels against LOS remained elevated following disease, whereas the IgG anti-NadA levels returned to acute-phase levels in the late convalescent phase. Among adults, the anti-LOS IgG levels were similar in acute-phase patient sera as in control sera, whereas anti-NadA IgG levels were significantly higher in acute-phase sera than in controls. The IgG antibody levels against LOS and NadA correlated moderately but significantly with serum bactericidal activity against MenA strains. Future studies on immune response during MenA disease should take into account the high levels of anti-MenA polysaccharide IgG commonly found in the population and seek to clarify the role of antibodies against subcapsular antigens in protection against MenA disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337382      PMCID: PMC2394845          DOI: 10.1128/CVI.00252-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  56 in total

1.  Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes.

Authors:  Pierre Nicolas; Gunnstein Norheim; Eric Garnotel; Saacou Djibo; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

2.  Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.

Authors:  D Martin; N Cadieux; J Hamel; B R Brodeur
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

3.  Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

4.  Improved techniques for the preparation of bacterial lipopolysaccharides.

Authors:  K G Johnson; M B Perry
Journal:  Can J Microbiol       Date:  1976-01       Impact factor: 2.419

5.  Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection.

Authors:  Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  J Infect Dis       Date:  2003-04-15       Impact factor: 5.226

6.  Human antibody responses to A and C capsular polysaccharides, IgA1 protease and transferrin-binding protein complex stimulated by infection with Neisseria meningitidis of subgroup IV-1 or ET-37 complex.

Authors:  N Brieske; M Schenker; T Schnibbe; M J Quentin-Millet; M Achtman
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

7.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

8.  Proteome analysis of Neisseria meningitidis serogroup A.

Authors:  Giulia Bernardini; Giovanni Renzone; Maurizio Comanducci; Roberta Mini; Simona Arena; Chiara D'Ambrosio; Stefania Bambini; Lorenza Trabalzini; Guido Grandi; Paola Martelli; Mark Achtman; Andrea Scaloni; Giulio Ratti; Annalisa Santucci
Journal:  Proteomics       Date:  2004-10       Impact factor: 3.984

9.  Meningococcal group A lipooligosaccharides (LOS): preliminary structural studies and characterization of serotype-associated and conserved LOS epitopes.

Authors:  J J Kim; N J Phillips; B W Gibson; J M Griffiss; R Yamasaki
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.

Authors:  G V Sierra; H C Campa; N M Varcacel; I L Garcia; P L Izquierdo; P F Sotolongo; G V Casanueva; C O Rico; C R Rodriguez; M H Terry
Journal:  NIPH Ann       Date:  1991-12
View more
  4 in total

1.  Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Authors:  Wendell D Zollinger; Elizabeth E Moran; Deborah H Schmiel
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

2.  Genetic and structural characterization of L11 lipooligosaccharide from Neisseria meningitidis serogroup A strains.

Authors:  Noëlle Mistretta; Delphine Seguin; Jerôme Thiébaud; Sandrine Vialle; Frédéric Blanc; Marina Brossaud; Philippe Talaga; Gunnstein Norheim; Monique Moreau; Bachra Rokbi
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

3.  Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Authors:  Elizabeth E Moran; Robert Burden; Joseph E Labrie; Zhiyun Wen; Xin-Min Wang; Wendell D Zollinger; Lan Zhang; Valerian B Pinto
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

4.  A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

Authors:  Olivier Manigart; Caroline Trotter; Helen Findlow; Abraham Assefa; Wude Mihret; Tesfaye Moti Demisse; Biruk Yeshitela; Isaac Osei; Abraham Hodgson; Stephen Laryea Quaye; Samba Sow; Mamadou Coulibaly; Kanny Diallo; Awa Traore; Jean-Marc Collard; Rahamatou Moustapha Boukary; Oumarou Djermakoye; Ali Elhaji Mahamane; Jean-François Jusot; Cheikh Sokhna; Serge Alavo; Souleymane Doucoure; El Hadj Ba; Mariétou Dieng; Aldiouma Diallo; Doumagoum Moto Daugla; Babatunji Omotara; Daniel Chandramohan; Musa Hassan-King; Maria Nascimento; Arouna Woukeu; Ray Borrow; James M Stuart; Brian Greenwood
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.